Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UC Irvine UCSF
Dates
study started
completion around
Principal Investigator
by Aaron B. Simon (uci)Ruben C. Fragoso (ucdavis)Steve E. Braunstein (ucsf)
Headshot of Aaron B. Simon
Aaron B. Simon
Headshot of Steve E. Braunstein
Steve E. Braunstein

Description

Summary

This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases.

Official Title

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients With Resectable Brain Metastases

Details

Keywords

Metastatic Malignant Neoplasm in the Brain, Brain Neoplasms, Neoplasms, Brain Surgery, Quality-of-Life Assessment, Stereotactic Radiosurgery, surgery, stereotactic radiosurgery, stereotactic radiosurgery, surgery

Eligibility

Locations

Lead Scientists at University of California Health

  • Aaron B. Simon (uci)
    Assistant Professor In Residence, Radiation Oncology, School of Medicine. Authored (or co-authored) 18 research publications
  • Ruben C. Fragoso (ucdavis)
    Professor of Clinical, MED: Radiation-Oncology, School of Medicine. Authored (or co-authored) 26 research publications
  • Steve E. Braunstein (ucsf)
    Dr. Braunstein is a radiation oncologist with a clinical interest in the treatment of pediatric, central nervous system, and soft tissue malignancies. He has expertise in modern radiation therapy techniques including stereotactic radiotherapy (Gamma Knife, Cyberknife, Linac-based SBRT), intraoperative radiotherapy, and intensity modulated radiation therapy. Dr. Braunstein earned his M.D.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
NRG Oncology
ID
NCT05438212
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 236 study participants
Last Updated